Nov 17, 2022 / 01:00PM GMT
Presentation
Nov 17, 2022 / 01:00PM GMT
=====================
Corporate Participants
=====================
* Baisong Mei
Editas Medicine, Inc. - Senior VP & Chief Medical Officer
* Gilmore OâNeill
Editas Medicine, Inc. - President & CEO
* Ron Moldaver
Editas Medicine, Inc. - IR
=====================
Conference Call Participants
=====================
* Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst
* Jay Olson
Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst
* Joel Lawrence Beatty
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst
* Liisa Ann Bayko
Evercore ISI Institutional Equities, Research Division - MD & Fundamental Research Analyst
* Lisa A. Walter
RBC Capital Markets, Research Division - Senior Associate
* Mani Foroohar
SVB Securities LLC, Research Division - Senior MD of Genetic Medicines and Senior Research Analyst
* Matthew
Editas Medicine Inc
(LTS:0IFK)
$
3.5
(0%)
Market Cap: 560.14 Mil
Enterprise Value: 453.79 Mil
PE Ratio: 0
PB Ratio: 80.89
GF Score: 48/100 Editas Medicine Inc Announces EDIT-101 Clinical Update Presentation Transcript
Nov 17, 2022 / 01:00PM GMT
Release Date Price:
$10.54
(-16.50%)
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot